EMA/33469/2021

European Medicines Agency decision

P/0026/2021

of 27 January 2021

on the acceptance of a modification of an agreed paediatric investigation plan for darvadstrocel (Alofisel) (EMEA-001561-PIP01-13-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0026/2021

of 27 January 2021

on the acceptance of a modification of an agreed paediatric investigation plan for darvadstrocel (Alofisel) (EMEA-001561-PIP01-13-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0253/2014 issued on 29 September 2014 and the decision P/0207/2020 issued on 16 June 2020,

Having regard to the application submitted by Takeda Pharma A/S on 3 September 2020 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 11 December 2020, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for darvadstrocel (Alofisel), suspension for injection, intralesional injection, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Takeda Pharma A/S, Dybendal Alle 10, 2630 – Taastrup, Denmark.

EMA/PDCO/623921/2020
Amsterdam, 11 December 2020

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001561-PIP01-13-M02

Scope of the application

Active substance(s):

Darvadstrocel

Invented name:

Alofisel

Condition(s):

Treatment of perianal fistula

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Suspension for injection

Route(s) of administration:

Intralesional injection

Name/corporate name of the PIP applicant:

Takeda Pharma A/S

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Takeda Pharma A/S submitted to the European Medicines Agency on 3 September 2020 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0253/2014 issued on 29 September 2014 and the decision P/0207/2020 issued on 16 June 2020.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 13 October 2020.

Scope of the modification

A timeline of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of perianal fistula

- the paediatric population from birth to less than 4 years;
- suspension for injection, intralesional use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset.

2. Paediatric investigation plan

2.1. Condition:

Treatment of perianal fistula

2.1.1. Indication(s) targeted by the PIP

Treatment of perianal fistula

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 4 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Suspension for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	3	Study 1) B-00200 and B-00368 Repeat dose toxicity study Study 2) B-00367 In vivo tumorigenicity study Study 3) C5114 and C5509 Biodistribution study to determine potential for cell spreading using quantitative PCR of donor cell DNA

Clinical studies	1	Study 4) Darvadstrocel-3004 Open-label, multi-centre non-comparative study to evaluate the activity of Darvadstrocel for the treatment of complex perianal fistulae
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2025
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of perianal fistula

Authorised indication(s):

- Alofisel is indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. Alofisel should be used only after conditioning of the fistulas (see section 4.2).

Authorised pharmaceutical form(s):

Suspension for injection

Authorised route(s) of administration:

Injection